Artelo Biosciences (ARTL) Operating Expenses (2014 - 2025)

Artelo Biosciences (ARTL) has reported Operating Expenses for 12 consecutive years, with $2.8 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Operating Expenses fell 26.92% year-over-year to $2.8 million in Q4 2025; TTM through Dec 2025 was $11.4 million, a 12.82% increase from a year earlier, with the FY2025 full-year figure at $11.4 million, up 12.82% from the prior year.
• Operating Expenses was $2.8 million for Q4 2025 at Artelo Biosciences, down from $3.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $3.8 million in Q4 2024 and troughed at $1.2 million in Q3 2024.
• A 5-year average of $2.5 million and a median of $2.5 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses slumped 54.28% in 2024 and surged 158.49% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at $2.6 million in 2021, then soared by 36.21% to $3.5 million in 2022, then retreated by 6.79% to $3.2 million in 2023, then rose by 17.65% to $3.8 million in 2024, then fell by 26.92% to $2.8 million in 2025.
• The last three Operating Expenses figures came in at $2.8 million (Q4 2025), $3.1 million (Q3 2025), and $3.2 million (Q2 2025), per Business Quant data.